Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1996 Apr;55(4):218–223. doi: 10.1136/ard.55.4.218

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

M J van der Veen 1, H J Dinant 1, C van Booma-Frankfort 1, G A van Albada-Kuipers 1, J W Bijlsma 1
PMCID: PMC1010141  PMID: 8733437

Abstract

OBJECTIVE: To investigate whether methotrexate (MTX) has a steroid sparing effect in the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). METHODS: We carried out a randomised double blind, placebo controlled study in 40 patients with PMR, six of whom also had clinical symptoms of GCA. A temporal artery biopsy specimen was available from 37 patients; GCA was found in six of the specimens. Among the six patients with clinical signs of GCA, three had a positive biopsy specimen. All patients were started on prednisone 20 mg/day, irrespective of clinical signs and biopsy result, supplemented with a weekly, blinded capsule containing either MTX 7.5 mg or placebo. The prednisone dose was decreased as soon as clinical symptoms disappeared and erythrocyte sedimentation rate, C reactive protein level, or both, had normalised. RESULTS: Twenty one patients were followed for two years, or at least one year after discontinuing medication. No differences were found between the MTX group and the placebo group concerning time to achieve remission, duration of remission, number of relapses, or cumulative prednisone doses. After 21 weeks the mean daily prednisone dose was reduced by 50%. Forty percent of all patients were able to discontinue prednisone within two years. Median duration of steroid treatment was 47.5 weeks (range 3-104). No serious complications from GCA were encountered. CONCLUSIONS: With a (rapid) steroid tapering regimen, it was possible to reduce the mean daily prednisone dose by 50% in 21 weeks and to cease prednisone in 40% of the patients within two years. With this regimen, no steroid sparing effect of MTX in a dosage of 7.5 mg/week was found.

Full text

PDF
218

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayoub W. T., Franklin C. M., Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med. 1985 Sep;79(3):309–315. doi: 10.1016/0002-9343(85)90309-2. [DOI] [PubMed] [Google Scholar]
  2. Behn A. R., Perera T., Myles A. B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis. 1983 Aug;42(4):374–378. doi: 10.1136/ard.42.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bengtsson B. A., Malmvall B. E. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand. 1981;209(5):337–345. doi: 10.1111/j.0954-6820.1981.tb11604.x. [DOI] [PubMed] [Google Scholar]
  4. Bengtsson B. A., Malmvall B. E. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum. 1981 Jul;24(7):899–904. doi: 10.1002/art.1780240706. [DOI] [PubMed] [Google Scholar]
  5. Chuang T. Y., Hunder G. G., Ilstrup D. M., Kurland L. T. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982 Nov;97(5):672–680. doi: 10.7326/0003-4819-97-5-672. [DOI] [PubMed] [Google Scholar]
  6. Delecoeuillerie G., Joly P., Cohen de Lara A., Paolaggi J. B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988 Sep;47(9):733–739. doi: 10.1136/ard.47.9.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. J Rheumatol. 1980 May-Jun;7(3):361–364. [PubMed] [Google Scholar]
  8. Fernandez-Herlihy L. Temporal arteritis: clinical aids to diagnosis. J Rheumatol. 1988 Dec;15(12):1797–1801. [PubMed] [Google Scholar]
  9. Goldsmith C. H., Smythe H. A., Helewa A. Interpretation and power of a pooled index. J Rheumatol. 1993 Mar;20(3):575–578. [PubMed] [Google Scholar]
  10. Healey L. A. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984 May;13(4):322–328. doi: 10.1016/0049-0172(84)90012-x. [DOI] [PubMed] [Google Scholar]
  11. Hellmann D. B. Immunopathogenesis, diagnosis, and treatment of giant cell arteritis, temporal arteritis, polymyalgia rheumatica, and Takayasu's arteritis. Curr Opin Rheumatol. 1993 Jan;5(1):25–32. doi: 10.1097/00002281-199305010-00005. [DOI] [PubMed] [Google Scholar]
  12. Hernández-García C., Soriano C., Morado C., Ramos P., Fernández-Gutiérrez B., Herrero M., Bañares A., Jover J. A. Methotrexate treatment in the management of giant cell arteritis. Scand J Rheumatol. 1994;23(6):295–298. doi: 10.3109/03009749409099276. [DOI] [PubMed] [Google Scholar]
  13. Hoffman G. S., Leavitt R. Y., Kerr G. S., Rottem M., Sneller M. C., Fauci A. S. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994 Apr;37(4):578–582. doi: 10.1002/art.1780370420. [DOI] [PubMed] [Google Scholar]
  14. Hunder G. G., Bloch D. A., Michel B. A., Stevens M. B., Arend W. P., Calabrese L. H., Edworthy S. M., Fauci A. S., Leavitt R. Y., Lie J. T. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 Aug;33(8):1122–1128. doi: 10.1002/art.1780330810. [DOI] [PubMed] [Google Scholar]
  15. Huston K. A., Hunder G. G. Giant cell (cranial) arteritis: a clinical review. Am Heart J. 1980 Jul;100(1):99–105. doi: 10.1016/0002-8703(80)90285-9. [DOI] [PubMed] [Google Scholar]
  16. Kyle V., Hazleman B. L. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis. 1993 Dec;52(12):847–850. doi: 10.1136/ard.52.12.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kyle V., Hazleman B. L. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis. 1989 Aug;48(8):662–666. doi: 10.1136/ard.48.8.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Myles A. B., Perera T., Ridley M. G. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol. 1992 Feb;31(2):103–105. doi: 10.1093/rheumatology/31.2.103. [DOI] [PubMed] [Google Scholar]
  19. Shiner R. J., Nunn A. J., Chung K. F., Geddes D. M. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet. 1990 Jul 21;336(8708):137–140. doi: 10.1016/0140-6736(90)91659-x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES